1. Home
  2. |Insights
  3. |Section 508 Compliance Takes Hit from the Federal Circuit

Section 508 Compliance Takes Hit from the Federal Circuit

Client Alert | less than 1 min read | 06.23.11

In a case of first impression, a split Federal Circuit panel in Allied Tech. Grp., Inc. v. U.S. (June 9, 2011) held that a contractor complied with the section 508 requirements for accessibility to computer systems by the handicapped simply by certifying with self-described “minor” exceptions. The dissenting judge reasoned that Congress had provided an exception process for the agency to follow which it had failed to do in this instance.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights